Evaluating the New Watchman FLX Pro 40 mm Device: A Case Study Series
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Philippe Taieb und 3 weiteren Autor:innen. Beteiligte Einrichtung: Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Cardiac Catheterization, Stroke. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Left atrial appendage closure (LAAC) is a well‐established alternative for stroke prevention in patients with atrial fibrillation (AF) who are not suitable for long‐term anticoagulation. The WATCHMAN FLX Pro 40 mm device is a novel advancement featuring a fluoropolymer coating to enhance thromboresistance and a size expansion to accommodate larger left atrial appendages (LAA). However, clinical data on this new device remains limited.
Objective
This study presents the first case series evaluating the procedural success, safety, and early outcomes of the 40 mm WATCHMAN FLX Pro device.
Methods
A total of nine patients underwent LAAC with the 40 mm WATCHMAN FLX Pro between July and November 2024. Pre‐procedural imaging, intraoperative guidance, procedural outcomes, and follow‐up imaging were analyzed. Procedural success was defined by the successful deployment of the device meeting “PASS” criteria, with no major complications.
Results
The study demonstrated a 100% procedural success rate, with all patients undergoing same‐day discharge. No procedural or periprocedural complications were observed. Follow‐up imaging at 4 months (available for 88.9% of patients) revealed no high‐grade device‐related thrombus (DRT), though some cases exhibited peridevice leaks, predominantly minor subfabric leaks.
Conclusion
The 40 mm WATCHMAN FLX Pro expands LAAC treatment options for patients with larger LAA anatomy, demonstrating a favorable safety and efficacy profile in this early experience. Larger studies with long‐term follow‐up are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
ORCID-Profile: Philippe Taieb, Marco Frazzetto, Steven J Filby
Zitieren
APA
Taieb, P., Frazzetto, M., Teixeira, P. S., & Filby, S. J. (2025). Evaluating the New Watchman FLX Pro 40 mm Device: A Case Study Series. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70036
Vancouver
Taieb P, Frazzetto M, Teixeira PS, Filby SJ. Evaluating the New Watchman FLX Pro 40 mm Device: A Case Study Series. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70036
BibTeX
@article{Taieb2025,
author = {Taieb, Philippe and Frazzetto, Marco and Teixeira, Pedro Soares and Filby, Steven J},
title = {Evaluating the New Watchman FLX Pro 40 mm Device: A Case Study Series},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70036}
}
EUVIMED